Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -21.92 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | 51.51 | 899.52 | 545.22 | 492.14 | 98.00 | 123.86 | 25.67 | 15.73 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | -47.4% | +626.3% | +2023.7% | +3028.4% | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.57 | 7.27 | 6.60 | 7.55 | 3.39 | 2.23 | 1.82 | 3.45 | 2.84 | 1.86 | 3.69 | 2.90 | 2.67 | 0.76 | 0.67 | 1.49 | 0.99 | 0.80 | 2.43 | 3.53 | 2.79 |
| — | +225.5% | +263.6% | +118.8% | +19.4% | +20.3% | -50.9% | +19.1% | +6.2% | +144.7% | +454.1% | +94.7% | +170.5% | -5.5% | -72.6% | -57.9% | -64.6% | -64.7% | -48.8% | -39.9% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | -654.2% | -13767.9% | -7535.9% | -6160.8% | -3470.5% | -3588.0% | -3179.6% | -3634.1% | — | — | — | — | — | — |
| — | — | — | — | — | — | — | +81.1% | -283.7% | -137.0% | -69.5% | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | -857.0% | -18819.5% | -10500.8% | -9718.3% | -5399.2% | -5452.1% | -4476.3% | -5577.0% | — | — | — | — | — | — |
| — | — | — | — | — | — | — | +84.1% | -245.2% | -134.6% | -74.3% | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | -786.3% | -17188.7% | -9153.2% | -9177.0% | -5219.0% | -5263.2% | -4393.3% | -5483.9% | — | — | — | — | — | — |
| — | — | — | — | — | — | — | +84.9% | -226.6% | -108.3% | -67.3% | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.8% | -6.1% | -8.1% | -14.6% | -19.8% | -16.9% | -15.7% | -14.2% | -12.9% | -10.1% | -26.4% | -34.4% | -25.6% | -40.3% | -53.3% | -45.4% | -36.0% | -36.5% | -31.1% | -21.4% | -14.2% |
| — | +63.9% | +48.4% | -2.7% | -52.7% | -67.4% | +40.7% | +58.8% | +49.4% | +75.0% | +50.4% | +24.4% | +28.9% | -10.6% | -71.3% | -112.0% | -153.7% | -200.4% | -214.2% | -36.5% | +46.1% | |
| ROA | -42.7% | -5.9% | -7.7% | -13.3% | -17.4% | -15.3% | -14.4% | -13.0% | -12.1% | -9.5% | -23.4% | -27.6% | -20.5% | -29.6% | -35.1% | -32.7% | -27.7% | -28.7% | -25.8% | -19.0% | -13.2% |
| — | +61.5% | +46.4% | -2.1% | -43.8% | -61.6% | +38.4% | +52.7% | +40.9% | +68.1% | +33.4% | +15.5% | +26.0% | -3.2% | -35.9% | -72.1% | -110.0% | -149.2% | -174.7% | -29.6% | +42.2% | |
| ROIC | -65.0% | -8.3% | -11.4% | -20.3% | -26.6% | -21.8% | -22.1% | -21.5% | -17.3% | -15.8% | -88.8% | — | — | — | -1170.8% | -96.5% | -49.9% | -44.4% | -44.2% | -35.0% | -22.6% |
| — | +61.8% | +48.6% | +5.2% | -53.3% | -38.2% | +75.0% | — | — | — | +92.4% | — | — | — | -2551.4% | -175.3% | -120.5% | -141.0% | -35.9% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.03 | 0.03 | 0.05 | 0.05 | 0.04 | 0.03 | 0.02 | 0.02 | 0.01 |
| — | -56.6% | -58.1% | -95.9% | -70.7% | -59.8% | -74.9% | -91.4% | -86.3% | -83.7% | -80.9% | -22.1% | -10.5% | -0.0% | +125.5% | +167.6% | +138.0% | +110.9% | +930.2% | +547.6% | +72.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.22 | 15.73 | 15.88 | 10.22 | 5.18 | 6.31 | 8.44 | 10.77 | 10.96 | 17.30 | 11.27 | 5.39 | 6.15 | 5.31 | 3.16 | 3.23 | 4.57 | 4.56 | 5.18 | 7.48 | 12.90 |
| — | +149.5% | +88.1% | -5.1% | -52.7% | -63.5% | -25.1% | +99.8% | +78.1% | +225.5% | +257.1% | +67.0% | +34.8% | +16.6% | -39.1% | -56.8% | -64.6% | -79.4% | -74.4% | -61.1% | +15.6% | |
| Quick Ratio | 10.22 | 15.73 | 15.88 | 10.22 | 5.18 | 6.31 | 8.44 | 10.77 | 10.96 | 17.30 | 11.27 | 5.39 | 6.15 | 5.31 | 3.16 | 3.23 | 4.57 | 4.56 | 5.18 | 7.48 | 12.90 |
| — | +149.5% | +88.1% | -5.1% | -52.7% | -63.5% | -25.1% | +99.8% | +78.1% | +225.5% | +257.1% | +67.0% | +34.8% | +16.6% | -39.1% | -56.8% | -64.6% | -79.4% | -74.4% | -61.1% | +15.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | -262.32 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRAX stock.
Praxis Precision Medicines, Inc.'s current P/E is -21.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Praxis Precision Medicines, Inc.'s business trajectory between earnings reports.